Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-funder" }, "data": [ { "type": "Grant", "id": "15995", "attributes": { "award_id": "1IK2HX003695-01A2", "title": "Improving Specialty Care Through Virtual Care Models", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2026-01-01", "end_date": "2030-12-31", "award_amount": null, "principal_investigator": { "id": 44448, "first_name": "Rebecca", "last_name": "Tisdale", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 3442, "ror": "", "name": "VETERANS ADMIN PALO ALTO HEALTH CARE SYS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "1 Background: Specialty care deserts—the absence of specialists in geographic regions—have led to an access 2 crisis for the VA. In addition to increasing wait times and causing delays in care, these access needs drive many 3 Veterans to seek care outside VA, resulting in fragmented care, increased risks for hospitalization and hospital 4 readmission, and higher costs. In response, VA has launched the Clinical Resource Hub (CRH) program, which 5 seeks to deliver virtual care from “hub” to “spoke” sites in VA. VISN 21 has begun implementing this model in 6 cardiology at several spoke sites, but little is known about how care utilization and quality within the program. 7 Significance/Impact: This work seeks to better understand the effects of a virtual model of specialty care, in 8 this case cardiology care, on Veterans’ care access and quality. In addition, it aligns closely with several VA and 9 HSR&D priorities, chiefly access to care, virtual care/telehealth, and advancing the goals of the MISSION Act. 10 Innovation: The CRH program and the virtual care model at its core have yet to be studied in depth, and there 11 is no research in progress regarding specialty CRH despite strong interest at the national VA level in 12 understanding how specialty CRH is used and associated outcomes. Given that virtual cardiology care was very 13 limited prior to the COVID-19 pandemic, cardiology CRH is particularly novel. Hence, this project would add to 14 the limited body of research examining virtual cardiology care in the VA. In addition, the proposed work seeks to 15 evaluate this virtual care model at a time of unprecedented choice for Veterans between in-person and virtual 16 care, and limited data on how best to integrate these modalities. 17 Specific Aims: The proposed CDA will offer mentorship and training for me to pursue the following aims: 18 Aim 1. Evaluate quality of cardiology care associated with CRH implementation with administrative data. 19 I will use adjusted difference-in-difference event studies to compare cardiology quality metric achievement for 20 patients who received cardiology care via CRH versus those who received conventional VA-based cardiology care. 21 Aim 2. Assess Veteran perceptions of quality of cardiology care delivered via CRH. 22 I will interview Veterans participating in the CRH program and their caregivers regarding their experiences and 23 perceptions of quality of CRH cardiology care and elicit suggestions for key metrics to focus on for improvement. 24 Aim 3. Construct intervention to track and improve access to high-quality, equitable care through CRH. 25 Building on finding from Aims 1 and 2, I will interview clinicians and employ a facilitated deliberative process with 26 an expert advisory group to construct and pilot an intervention to improve quality. 27 Methodology: In Aim 1, I will use a difference-in-difference event study design to assess the impact of the program 28 on a battery of validated and/or guideline-based quality of cardiology care metrics. In Aim 2, guided by the Fortney 29 model of care access and quality, I will conduct semi-structured interviews of Veterans and caregivers receiving 30 care through the VISN 21 CRH program to understand their experiences with the CRH program and what outcomes 31 they recommend to include in a quality improvement intervention. In Aim 3, I will interview clinicians (Aim 3.1) and 32 conduct a facilitated deliberation process (Aim 3.2) to inform the construction of an intervention (proactive panel 33 management using a clinical dashboard tool) to track and improve quality of care and pilot the intervention. 34 Next Steps/Implementation: To continue moving this research into practice to improve health outcomes for 35 Veterans, I will extend the analysis of cardiology quality of care to compare cardiology care in the community to 36 CRH care. In addition, I will assess the effect of the intervention constructed in Aim 3 on patient outcomes and 37 clinician satisfaction via a hybrid implementation-effectiveness trial. I will continue to work with operational partners 38 to ensure cardiology CRH is improving access to high-quality cardiology care for Veterans. This project supports 39 my goal of becoming an independent VA health services researcher and leader in optimizing cardiovascular 40 disease care access, value, and equity for Veterans through virtual care innovations and implementation.", "keywords": [ "Achievement", "Address", "Area", "COVID-19 pandemic", "California", "Cardiology", "Cardiovascular Diseases", "Cardiovascular system", "Caregivers", "Caring", "Characteristics", "Cladribine", "Clinical", "Clinical Services", "Communities", "Community Health Care", "Dangerousness", "Data", "Disease", "Ensure", "Equity", "Evaluation", "Event", "Geographic Locations", "Goals", "Guidelines", "Health", "Health Services", "Health Services Accessibility", "Heart failure", "Homogeneously Staining Region", "Hospitalization", "Hospitals", "Improve Access", "Intervention", "Interview", "Medical", "Mentors", "Mentorship", "Methodology", "Methods", "Modality", "Modeling", "Morbidity - disease rate", "Nevada", "Outcome", "Pacific Islands", "Patient-Focused Outcomes", "Patients", "Perception", "Persons", "Physicians", "Policies", "Positioning Attribute", "Process", "Qualitative Methods", "Quality of Care", "Recommendation", "Research", "Research Design", "Research Personnel", "Resources", "Risk", "Rural Health", "Safety", "Site", "Specialist", "Structure", "Suggestion", "Telemedicine", "Telephone", "Testing", "Time", "Training", "Training Activity", "Veterans", "Visit", "Wait Time", "Work", "adverse outcome", "care fragmentation", "care seeking", "care utilization", "clinical implementation", "connected care", "cost", "dashboard", "design", "effectiveness/implementation trial", "experience", "follow-up", "health economics", "hospital readmission", "hospitalization rates", "implementation efforts", "implementation science", "improved", "innovation", "insight", "interest", "intervention effect", "medical specialties", "mortality", "novel", "operation", "patient subsets", "pilot test", "preference", "programs", "rapid growth", "research to practice", "response", "rural counties", "satisfaction", "sociodemographics", "southern nevada", "telehealth", "therapy design", "tool", "virtual", "virtual delivery", "virtual health care", "virtual model" ], "approved": true } }, { "type": "Grant", "id": "5582", "attributes": { "award_id": "3R01NS118760-02S1", "title": "Peripheral Tissue Biomarker for Premorten Diagnosis of Lewy Body Dementia", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 19352, "first_name": "Debra J.", "last_name": "Babcock", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-01", "end_date": "2025-06-30", "award_amount": 975214, "principal_investigator": { "id": 19353, "first_name": "SHU G", "last_name": "CHEN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19354, "first_name": "Allison L", "last_name": "Kraus", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 497, "ror": "https://ror.org/051fd9666", "name": "Case Western Reserve University", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "This supplemental application will examine the effects of COVID-19 on the disease severity and changes in diagnostic biomarkers of Lewy body dementia (LBD) affecting 1.4 million people in the U.S. Recent studies have shown that patients with dementia are more susceptible to COVID-19 infection, however, the effects of COVID- 19 infection on the severity and progression of dementia has yet to be systematically examined. Further, it is unclear how overlapping symptoms between Lewy body diseases and those reported for COVID-19 including anosmia and various neurological symptoms might further complicate clinical evaluation and diagnosis of LBD. We will address this research question by testing patients with LBD for active or prior COVID-19 infection and examining changes in clinical manifestations and diagnostic biomarkers. Within the scope of our parent R01 award and in response to the NIH Notice of Special Interest (NOT-NS-21-037), we propose to consider COVID-19 status as a biological variable in our human subject studies on LBD with concomitant biomarker assessments, to be accomplished in two aims. Aim 1 will examine if COVID-19 infection alters disease severity and progression in LBD patients. LBD patients will be tested for current and prior COVID-19 infection and undergo standardized clinical assessments and neurological evaluations for parkinsonism, cognitive decline, and neuropsychiatric symptoms. Aim 2 will assess changes in diagnostic tissue and neuroimaging biomarkers in LBD patients affected by COVID-19 infection. Our proposed research will provide molecular and neurophysiological insights into the effects of COVID-19 infection on clinical progression of LBD, with the ultimate goal of guiding preventative and therapeutic interventions.", "keywords": [ "Address", "Affect", "Anosmia", "Antibodies", "Award", "Biological", "Biological Assay", "Biological Markers", "Biopsy", "Blood specimen", "Brain", "COVID-19", "COVID-19 pandemic", "COVID-19 susceptibility", "COVID-19 testing", "Clinic", "Clinical", "Clinical assessments", "Computerized Medical Record", "Control Groups", "Dementia", "Dementia with Lewy Bodies", "Detection", "Development", "Diagnosis", "Diagnostic", "Differential Diagnosis", "Disease", "Disease Progression", "Early Diagnosis", "Enrollment", "Evaluation", "Foundations", "Funding", "Future", "Goals", "Hospitalization", "Impaired cognition", "Lewy Body Dementia", "Lewy Body Disease", "Literature", "Long-Term Effects", "MRI Scans", "Magnetic Resonance Imaging", "Measures", "Molecular", "Motor", "Neurologic", "Neurologic Symptoms", "Olfactory Mucosa", "Outcome", "Parents", "Parkinson&apos", "s Dementia", "Parkinsonian Disorders", "Patient Care", "Patients", "Peripheral", "Recording of previous events", "Records", "Reporting", "Research", "Risk Factors", "SARS-CoV-2 infection", "Saliva", "Severities", "Severity of illness", "Site", "Skin", "Skin Tissue", "Standardization", "Study Subject", "Symptoms", "Tauopathies", "Testing", "Therapeutic", "Therapeutic Intervention", "Time", "United States National Institutes of Health", "Visit", "alpha synuclein", "bioinformatics tool", "brain health", "clinical Diagnosis", "comorbidity", "diagnostic biomarker", "follow up assessment", "follow-up", "human subject", "illness length", "improved", "insight", "interest", "nasal swab", "nervous system disorder", "neuroimaging marker", "neurophysiology", "neuropsychiatric symptom", "non-motor symptom", "preventive intervention", "progression marker", "protein aggregation", "recruit", "research clinical testing", "response", "synucleinopathy", "tau Proteins", "tau aggregation", "tissue biomarkers", "vaccination outcome", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "10523", "attributes": { "award_id": "1DP2AI171120-01", "title": "Crossing scales to predict and prevent bat virus zoonoses in a Madagascar ecosystem", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6054, "first_name": "Eun-Chung", "last_name": "Park", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-05", "end_date": "2027-08-31", "award_amount": 460576, "principal_investigator": { "id": 26531, "first_name": "Cara", "last_name": "Brook", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The wide-reaching impacts of the COVID-19 pandemic highlight the extreme threat posed by the cross-species emergence of zoonotic pathogens. Bats (order: Chiroptera) are the natural reservoir hosts for the majority of the world’s most virulent zoonotic viruses, including Hendra and Nipah henipaviruses, Ebola and Marburg filoviruses, and SARS, MERS, and now SARS-CoV-2 coronaviruses. Remarkably, bats exhibit little demonstrable disease upon infection with viruses that cause extreme pathology in other mammals, likely in part due to their unique anti-inflammatory molecular adaptations, which are thought to have evolved to mitigate the accumulation of physiological damage accrued during flight. Surprisingly, isolated island bat communities around the world support the endemic circulation of numerous viruses in populations below the critical community size required for persistence of related pathogens in other hosts. Since cross-species spillover of several bat-borne viruses bears a distinctive seasonal signature, coincident with the timing of reproductive and nutritional stress for the bat hosts in question, disentangling the mechanisms governing the transmission, circulation, and persistence of these viruses in wild bat populations is of critical public health interest. In part with the research initiatives proposed here, we will use molecular and serological tools to develop a longitudinal time series of immunological and infection data for henipaviruses and coronaviruses circulating in wild fruit bats in Madagascar, leveraging samples collected in our longterm wildlife surveillance effort. Bats are widely consumed as a source of human food in Madagascar, and preliminary data from our research group demonstrates serological signatures of prior human exposure to these zoonotic viruses across the island. We propose to fit disparate dynamical models to the resulting population-level data in order to distinguish mechanisms underpinning seasonal viral shedding pulses and concomitant transmission in these bat hosts. In addition to population-level studies, we will also construct within-host models of viral control in a single bat immune system, which we will fit to experimental infection data from Betacoronavirus-challenged bats in the laboratory, with the aim of deciphering the mechanisms which motivate viral shedding. Our project aims to simultaneously develop molecular tools of bat cell lines and viruses with which to support within-host studies in our own Madagascar system. Finally, we will build on population-level and within-host studies to model and implement a vaccine intervention designed to eradicate circulating henipavirus from a test-population of Madagascar fruit bats. Broadly, our project aims to use a uniquely integrative combination of field, molecular, and modeling tools to enable the prediction and prevention of bat virus spillover events before they occur.", "keywords": [ "2019-nCoV", "Address", "African", "Animals", "Anti-Inflammatory Agents", "Biology", "Blood Circulation", "COVID-19 pandemic effects", "Canis familiaris", "Case Fatality Rates", "Cell Line", "Chicago", "Chiroptera", "Clinical", "Collaborations", "Communicable Diseases", "Communities", "Consumption", "Coronavirus", "Coupled", "Data", "Discipline", "Disease", "Doctor of Philosophy", "Ebola", "Ecology", "Ecosystem", "Evolution", "Exhibits", "Exposure to", "Filovirus", "Food", "Fruit", "Future", "Goals", "Hendra Virus", "Henipavirus", "Henipavirus Infections", "Human", "Immune", "Immune system", "Immunity", "Immunologics", "Infection", "Infection Control", "Innate Immune Response", "Intervention", "Island", "Jamaican", "Laboratories", "Learning", "Link", "Literature", "Madagascar", "Mammals", "Marburgvirus", "Measles", "Middle East Respiratory Syndrome", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Molecular", "Molecular Computations", "Molecular Immunology", "Monitor", "Nature", "Nutritional", "Paramyxovirus", "Pathology", "Pattern", "Periodicity", "Physiologic pulse", "Physiological", "Physiology", "Population", "Population Sizes", "Population Study", "Postdoctoral Fellow", "Prevention", "Process", "Public Health", "Rabies virus", "Recommendation", "Recrudescences", "Regimen", "Research", "Resources", "SARS coronavirus", "Sampling", "Seasonal Variations", "Series", "Serology", "Severe Acute Respiratory Syndrome", "Shapes", "Source", "Stress", "System", "Techniques", "Testing", "Time", "United States National Institutes of Health", "Universities", "Ursidae Family", "Vaccinated", "Vaccination", "Vaccines", "Viral", "Viral Load result", "Virulent", "Virus", "Virus Diseases", "Virus Shedding", "Work", "Zoonoses", "antiviral immunity", "bat-borne", "betacoronavirus", "chronic infection", "cost effective", "cross-species transmission", "design", "experience", "exposed human population", "field study", "health economics", "immunopathology", "infectious disease model", "innovation", "interest", "mathematical model", "molecular modeling", "novel", "pandemic preparedness", "pathogen", "post-doctoral training", "prevent", "professor", "reproductive", "spillover event", "stressor", "therapy design", "tool", "transmission process", "vaccine distribution", "viral transmission", "willingness", "zoonotic spillover" ], "approved": true } }, { "type": "Grant", "id": "5722", "attributes": { "award_id": "1R01AA029804-01", "title": "Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Eye Institute (NEI)" ], "program_reference_codes": [], "program_officials": [ { "id": 19733, "first_name": "LAURA ELIZABETH", "last_name": "Kwako", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-25", "end_date": "2024-08-31", "award_amount": 1128033, "principal_investigator": { "id": 19734, "first_name": "DAVID H", "last_name": "GUSTAFSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19735, "first_name": "Marie-Louise", "last_name": "Mares", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "/ ABSTRACT The combination of COVID-19 and alcohol/substance use disorders exacerbates a wide range of existing problems, including the likelihood of contracting COVID and severity of consequences, pandemic-related stresses that trigger alcohol and substance use, loss of jobs and healthcare access, increased interpersonal violence, and overarching systemic inequities. Interventions are needed to address these serious problems, which are likely to persist even after widespread availability of COVID vaccines. In response to PAR 20-243, this R01 project is a Hybrid II RCT/implementation study modifying and testing two of our alcohol smartphone interventions to address the fallout from COVID. We propose a 3-arm RCT comparing a control vs. a drinker-focused intervention vs. a family-focused intervention. The drinker-focused intervention (ACHESS-C) is an extension of our evidence-based Addiction–Comprehensive Health Enhancement Support system (ACHESS), augmented with COVID resources. The family-focused intervention (FamCHESS-C) combines ACHESS-C services with evidence-based Alcohol Behavioral Couple Therapy services to help both drinker and partner with behavior change, relationship problems, and general well-being. In the proposed 8-month trial plus 4-month follow-up, 198 dyads (drinker + family member) will be randomly assigned to: 1) Smartphone control: both receive a smartphone with standard support and crisis numbers; 2) ACHESS-C: drinker receives a phone with ACHESS-C, partner receives a phone with support and crisis numbers; 3) Fam-CHESS-C: both receive phone with FamCHESS-C. The project has the following aims: Aim 1: Complete refinements to the FamCHESS-C app. Aim 2: Conduct a balanced RCT to test the following outcomes: Primary: 1) drinker % heavy drinking days, 2) dyad quality of life. Secondary: 3) dyad relationship satisfaction, 4) dyad psychological/physical conflict, 5) drinker no heavy drinking days, 6) drinker % days alcohol/drug use, 7) dyad COVID vaccination rates, 8) drinker alcohol- and drug-related problems. Exploratory: 9) partner % days alcohol/drug use, 10) dyad crisis healthcare use, 11) dyad technology satisfaction. We hypothesize that outcomes will be more favorable in FamCHESS-C relative to ACHESS-C, and both will be more favorable relative to smartphone control. Aim 3: Examine mediation effects of dyad's competence, relatedness, and motivation; drinker's interim change in % days of alcohol and drug use, and extent of app use for comparisons of ACHESS-C and FamCHESS-C. Examine moderation of effects of condition by drinker sex, severity of drinker’s baseline alcohol use, drinker engagement in treatment for AUD/SUD, and dyad’s baseline relationship satisfaction. Aim 4: Conduct a small-scale (20 dyads) formative evaluation using an implementation science model to collect qualitative data on perceptions of difficulties and benefits of ACHESS-C and FamCHESS-C use.", "keywords": [ "Address", "Adult", "Al-Anon", "Alcohol consumption", "Alcoholic beverage heavy drinker", "Alcohols", "American", "Behavior Therapy", "Behavioral", "COVID-19", "Cellular Phone", "Child", "Communication", "Competence", "Conflict (Psychology)", "Contracts", "Control Groups", "Couples Therapy", "Data", "Disease", "Drug usage", "Evidence based intervention", "Family", "Family member", "Feedback", "Funding", "Health", "Health Insurance", "Healthcare", "Heavy Drinking", "Hybrids", "Interpersonal Violence", "Intervention", "Job loss", "Measures", "Mediating", "Mediation", "Mediator of activation protein", "Modeling", "Motivation", "Names", "National Institute on Alcohol Abuse and Alcoholism", "Outcome", "Perception", "Personal Satisfaction", "Persons", "Pharmaceutical Preparations", "Phase", "Quality of life", "Randomized", "Recovery", "Resources", "Risk", "Service delivery model", "Services", "Severities", "Spouses", "Stress", "Substance Use Disorder", "Sum", "Support System", "Technology", "Telephone", "Testing", "Time", "United States National Institutes of Health", "Vaccination", "Vaccines", "addiction", "alcohol comorbidity", "alcohol intervention", "arm", "base", "behavior change", "comorbidity", "coping", "coronavirus disease", "design", "digital health", "digital intervention", "disorder later incidence prevention", "drinking", "effectiveness testing", "evidence base", "follow up assessment", "follow-up", "formative assessment", "health care availability", "health disparity", "high risk drinking", "implementation science", "implementation study", "improved", "member", "pandemic disease", "primary outcome", "psychoeducation", "psychologic", "randomized trial", "recruit", "response", "satisfaction", "secondary outcome", "sex", "smartphone Application", "social", "substance use", "theories", "tool", "usability" ], "approved": true } }, { "type": "Grant", "id": "5608", "attributes": { "award_id": "3UM1AI148452-02S1", "title": "Vanderbilt Vaccine and Treatment Evaluation Unit", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19420, "first_name": "Gail H.", "last_name": "Tauscher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-03-25", "end_date": "2021-11-30", "award_amount": 192338, "principal_investigator": { "id": 19421, "first_name": "Clarence Buddy", "last_name": "Creech", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 456, "ror": "https://ror.org/05dq2gs74", "name": "Vanderbilt University Medical Center", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this UM1 proposal is to use the remarkable research infrastructure at Vanderbilt University Medical Center and collaborating sites (Washington University, University of Pittsburgh, and University of Pennsylvania) to conceptualize, design, implement, and analyze clinical research studies across a wide variety of pathogens, infectious diseases, and populations as a Vaccine and Treatment Evaluation Unit (VTEU). Vanderbilt University Medical Center was among the first VTEUs funded and has led pivotal studies of influenza, pertussis, pneumococcus, smallpox, and malaria vaccines. The Vanderbilt VTEU has a proven capacity to enroll healthy populations rapidly, including participating in two NIH- directed influenza pandemic responses since 2009, as well as expertise enrolling special populations such as pregnant women, infants and children, adults with underlying medical comorbidities, and the elderly. In the current application, we have expanded our ability to recruit across the lifespan and across multiple pathogens, including increased expertise in sexually transmitted infections, malaria, and novel approaches to conducting clinical trial visits in the home setting. The Vanderbilt VTEU has also led efforts to train the next generation of vaccinologists and clinical trial experts in infectious diseases, including the development of a vaccinology fellowship, participation of fellows and junior faculty in protocol teams and data safety committees, and encouraging concept development by junior faculty. The Vanderbilt VTEU is also committed to working collaboratively with the newly formed Infectious Diseases Leadership Group to articulate priorities for ID research.", "keywords": [ "Academic Medical Centers", "Adult", "Age", "Area", "Award", "Bacterial Infections", "Biological", "Biological Assay", "Child", "Childhood", "Clinical", "Clinical Investigator", "Clinical Research", "Clinical Trials", "Communicable Diseases", "Conduct Clinical Trials", "Data", "Development", "Disease", "Education", "Elderly", "Emerging Communicable Diseases", "Enrollment", "Environment", "Evaluation", "Faculty", "Feasibility Studies", "Fellowship", "Fostering", "Funding", "Geography", "Goals", "Home", "Human", "Immune response", "Immunity", "Immunization", "Immunologist", "Individual", "Infant", "Infection", "Influenza", "Institution", "International", "Intervention", "Laboratories", "Laboratory Scientists", "Lead", "Leadership", "Licensure", "Longevity", "Malaria", "Malaria Vaccines", "Medical", "Medical center", "Mentors", "Mentorship", "Methods", "Modeling", "Mycoses", "Nurses", "Parasitic infection", "Pathogenesis", "Pennsylvania", "Pertussis Vaccine", "Peru", "Pharmaceutical Preparations", "Phase", "Physicians", "Pneumococcal vaccine", "Population", "Population Heterogeneity", "Positioning Attribute", "Pregnant Women", "Prevention", "Principal Investigator", "Procedures", "Process", "Protocols documentation", "Research", "Research Infrastructure", "Research Personnel", "Safety", "Scientist", "Sexually Transmitted Diseases", "Site", "Smallpox Vaccine", "Special Population", "Standardization", "Systems Biology", "Tissues", "Training", "United States National Institutes of Health", "Universities", "Vaccination", "Vaccine Research", "Vaccines", "Viral", "Virus Diseases", "Visit", "Washington", "Work", "antibiotic resistant infections", "base", "career", "career development", "clinical research site", "comorbidity", "design", "early phase clinical trial", "emerging pathogen", "ethnic diversity", "experience", "immunogenicity", "influenza virus vaccine", "innovation", "next generation", "novel", "novel strategies", "novel therapeutics", "novel vaccines", "pandemic influenza", "pathogen", "recruit", "research study", "respiratory", "response", "tool", "vaccine trial", "vaccinology", "volunteer" ], "approved": true } }, { "type": "Grant", "id": "5573", "attributes": { "award_id": "3R01AI088364-12S1", "title": "Monogenic basis of resistance to SARS-CoV2 and predisposition to severe COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19329, "first_name": "Deborah", "last_name": "Hodge", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2010-04-06", "end_date": "2023-03-31", "award_amount": 446039, "principal_investigator": { "id": 19330, "first_name": "Jean-Laurent", "last_name": "Casanova", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19331, "first_name": "Shen-Ying", "last_name": "Zhang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 763, "ror": "https://ror.org/0420db125", "name": "Rockefeller University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "In December 2019, a novel coronavirus (SARS-CoV-2) emerged in the city of Wuhan, China, and quickly spread worldwide, with an increasing number of cases and deaths. In populations naive to this new pathogen, there has been immense inter-individual clinical variability among infected individuals, ranging from asymptomatic infection to lethal coronavirus infectious disease-19 (COVID-19), which is typically due to pneumonitis and rarely to encephalitis. The infection to severe/life-threatening ratio is estimated to be < 1/1,000 in people <20 years, around 5/1,000 in people 20-50 years, >1/100 over 50 years, and > 1/10 over 80 years. Underlying medical conditions also greatly increase the risk of severe COVID-19. On the other hand, rare cases of apparent resistance to the infection itself have also been identified (viral PCR-negative and seronegative individuals despite repeated and confirmed exposure). In this context, we hypothesize that monogenic inborn errors of immunity (IEI) may underlie life-threatening COVID-19 infections in previously healthy, young individuals (<50 years), whereas monogenic inborn variations of resistance (IVR) may protect other individuals from SARS-CoV- 2 infection. Both hypotheses are based on 25 years of studies of a wide range of other viral infections, for which IEI (e.g. influenza virus pneumonitis) and IVR (e.g. resistance to human immunodeficiency virus) have been identified. We will recruit both IEI and IVR cohorts not only in the USA but also, importantly, at the international level; search for candidate disease-causing variants using a cutting-edge strategy developed in our laboratory to analyze whole-exome sequencing (WES) data; and perform in-depth functional studies to characterize the products of candidate genotypes biochemically, and to analyze the corresponding patients’ cells immunologically. Our program aims to discover the human genetic and immunological basis of both severe “idiopathic” COVID- 19 and natural resistance to SARS-CoV-2. Our preliminary results are exciting. In less than 2 months, we and Helen Su (NIAID) have organized the global and growing “COVID Human Genetic Effort” (CHGE), with over 400 collaborators and 40 sequencing hubs in 50 countries (www.covidhge.com). In the last month, our own hub sequenced over 100 patients in the IEI cohort and enrolled 2 individuals in the IVR cohort. We have already selected 5 promising candidate genes (IKFZ1, POLR3C,TLR7, IRF7, IL22), which are all involved in anti-viral interferon immunity. Our program focuses on a timely problem (severe COVID in previously healthy young patients and individuals naturally resistant to infection), tests a bold but plausible hypothesis (monogenic basis for both groups of outliers), and uses cutting-edge genetic and mechanistic studies (including the study of leukocyte subsets and induced pluripotent stem cells (iPSC)-derived pulmonary epithelial cells). Our project will permit genetic diagnosis and counseling, while facilitating the development of novel preventive and therapeutic strategies including anti-viral drugs (e.g. aimed at restoring a deficient immunity or blocking viral entry) and vaccines (e.g. aimed at boosting certain immunological pathways) in both genetic and non-genetic cases.", "keywords": [ "Acyclovir", "Affect", "Alleles", "Architecture", "Biochemical", "Brain Stem", "Candidate Disease Gene", "Cells", "Child", "Childhood", "Clinical", "Collection", "Communicable Diseases", "Complication", "Country", "Data", "Disease", "Encephalitis", "Enrollment", "Family", "Fibroblasts", "Funding", "Genes", "Genetic", "Genetic Counseling", "Genetic Heterogeneity", "Genetic Predisposition to Disease", "Genetic study", "Genotype", "Hereditary Disease", "Herpes encephalitis", "Herpesvirus 1", "Heterogeneity", "Human Genetics", "IFNAR1 gene", "IRF3 gene", "Immunity", "Immunologics", "Impairment", "Individual", "Infection", "Interferon-alpha", "Interferons", "International", "Laboratories", "Lesion", "Leukocytes", "Life", "Mediating", "Mendelian disorder", "Minority", "Modeling", "Molecular", "Molecular Diagnosis", "Molecular Genetics", "Mutation", "Neuraxis", "Neurologic", "Neurons", "Olfactory Nerve", "Organ", "Parents", "Pathogenesis", "Pathway interactions", "Patients", "Penetrance", "Phenotype", "Physiological", "Population", "Primary Infection", "Privatization", "Prosencephalon", "RIPK1 gene", "RIPK3 gene", "Research", "Resistance", "Solid", "Survivors", "TBK1 gene", "TLR3 gene", "TNF receptor-associated factor 3", "Techniques", "Testing", "Trigeminal nerve structure", "United States National Institutes of Health", "Validation", "Variant", "Viral Encephalitis", "Work", "base", "candidate selection", "clinical care", "cohort", "congenital immunodeficiency", "design", "exome sequencing", "genetic analysis", "genetic linkage analysis", "genome sequencing", "genome-wide", "genome-wide linkage", "induced pluripotent stem cell", "innovation", "kindred", "mutant", "next generation sequencing", "novel", "novel therapeutic intervention", "recruit", "response", "trait", "transcriptome sequencing", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "10435", "attributes": { "award_id": "5R01GM140564-03", "title": "Merging machine learning and mechanistic models to improve prediction and inference in emerging epidemics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 12060, "first_name": "Han", "last_name": "Nguyen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-02-01", "end_date": "2024-12-31", "award_amount": 458952, "principal_investigator": { "id": 23970, "first_name": "Jessie", "last_name": "Edwards", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 23971, "first_name": "Justin", "last_name": "Lessler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "When an outbreak of an established or emerging infectious disease occurs we ask a standard set of questions that are critical to a lifesaving public health response: Where will future incidence occur? How many cases will there be? And where can we most effectively intervene? The proposed research is motivated by real world instances where answering these questions was critical to making practical public health decisions, and current methods came up short: from deciding if and where to build additional Ebola Treatment Units in the 2014-15 West African Ebola epidemic, to identifying priority districts where oral cholera vaccine should be used in the 2016-17 cholera outbreak in Yemen, to picking locations where sufficient cases might occur to selecting and prioritizing interventions to slow the spread of COVID-19 worldwide. Forecasts informing such decisions are typically generated either using an epidemic model that relies on knowledge of the disease transmission mechanism and epidemic theory or using a statistical model to project the expected number of cases based on the relationship between covariates and observed counts. However, both approaches are subject to limitations, particularly early in an epidemic when few cases are observed. This project is based on the overarching scientific premise that inferences that combine the strengths of mechanistic epidemic models and statistical covariate models will substantially outperform either approach alone in forecasting and making decisions to confront emerging infectious disease threats. Specifically, this project aims to (1) Develop a framework to forecast incidence in ongoing outbreaks that merges mechanistic and machine learning approaches; (2) Validate the framework using retrospective data and apply the framework to inform decision making in emerging epidemics; (3) Integrate this inferential forecasting framework into causal decision theory to optimize critical actions in the public health response to emerging epidemics; and (4) Develop accessible and extensible tools for forecasting and decision analysis in infectious disease epidemics. We will validate these approaches using rigorous simulation studies and by applying the proposed approaches to retrospective data from important recent epidemics (e.g., Ebola, Cholera and COVID-19, as mentioned above). We will prospectively apply our approach to inform the response to emerging disease threats that occur during the project period, including the ongoing COVID-19 pandemic. To ensure that the tools developed are useful, efficient, and user friendly, we will work with international humanitarian organizations responding to epidemics. Successful completion of these aims will provide a flexible and validated framework for forecasting and decision making during ongoing epidemics, while allowing for innovation in mechanistic and statistical approaches. In doing so it will provide tools to optimize responses and reduce morbidity and mortality during public health crises.", "keywords": [ "African", "Algorithms", "Area", "COVID-19", "COVID-19 pandemic", "Cholera", "Cholera Vaccine", "Communicable Diseases", "Community Health", "Cost utility", "Data", "Data Set", "Decision Analysis", "Decision Making", "Decision Theory", "Disease", "Disease Outbreaks", "Ebola", "Emerging Communicable Diseases", "Ensure", "Epidemic", "Evaluation", "Fogs", "Future", "Geographic Locations", "Incidence", "International", "Intervention", "Knowledge", "Liberia", "Link", "Location", "Machine Learning", "Methods", "Modeling", "Morbidity - disease rate", "Online Systems", "Oral", "Policies", "Public Health", "Research", "Research Personnel", "Series", "Shapes", "Statistical Algorithm", "Statistical Methods", "Statistical Models", "System", "Time", "Translating", "Update", "War", "Work", "Yemen", "base", "case-based", "curve fitting", "dashboard", "disease transmission", "experience", "flexibility", "improved", "innovation", "mortality", "multidimensional data", "programs", "prospective", "response", "simulation", "sound", "surveillance data", "theories", "tool", "transmission process", "user-friendly" ], "approved": true } }, { "type": "Grant", "id": "5546", "attributes": { "award_id": "3P20GM103546-10S1", "title": "Surveillance genome sequencing to detect SARS-CoV-2 virus variants in Montana", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 19254, "first_name": "Sheila", "last_name": "Caldwell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2011-09-01", "end_date": "2022-07-31", "award_amount": 704474, "principal_investigator": { "id": 19255, "first_name": "BRUCE E", "last_name": "BOWLER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 776, "ror": "https://ror.org/0078xmk34", "name": "University of Montana", "address": "", "city": "", "state": "MT", "zip": "", "country": "United States", "approved": true }, "abstract": "Montana is a state with large rural and Tribal Nations populations. Both groups have been underrepresented in whole genome sequencing of SARS-CoV-2 variants and the state of Montana lags significantly behind the country as a whole in sequencing data available from patients infected with SARS-CoV-2. Given the emergence of dangerous SARS-CoV-2 variants with higher viral transmissibility and reduced response to monoclonal antibody therapy and vaccine efficacy, lack of sequencing data is a critical problem for the Montana state Department of Public Health and Human Services (DPHHS) in mounting an appropriate response to the pandemic. Furthermore, sequencing data will be particularly important for understanding viral transmission in Tribal Nations, which have been disproportionately affected by the pandemic. This supplement to the Center for Biomolecular Structure and Dynamics COBRE grant will allow whole genome sequencing and analysis of >3000 SARS-CoV-2 viruses isolated from patients in the state of Montana, including those living in rural and Tribal communities. General sequencing results will be made publicly available, except Tribal samples unless Tribal approval is given, through GenBank and GISAID to facilitate broader analysis of the emergence of variants of concern (VOC) and variants of interest (VOI) in the United States and will be communicated directly to the Montana DPHHS and participating Tribal Nations so that they can adjust their responses to the pandemic. We take advantage of the CLIA-certified SARS-CoV-2 testing facility on the University of Montana campus, our expertise in whole genome sequencing and our established relationships with Tribal Nations in Montana to accomplish the goals of this SARS-CoV-2 sequencing supplement. The analysis of these data will focus on three specific aims: Specific Aim 1: What is the genetic structure of SARS-CoV-2 variants across Montana communities and how does this variation compare to regional, national, and global SARS-CoV-2 diversity? Specific Aim 2: Does the genetic composition of circulating SARS-CoV-2 variants differ between rural versus metropolitan and Tribal versus non-Tribal communities in Montana? Specific Aim 3: Are specific outbreaks associated with known or putative novel variants of interest and/or concern? Overall, the project will provide critical new insight into how more dangerous variants of SARS-CoV-2 arise and spread in a rural state and among the disproportionately-effected Tribal Nations in Montana that will allow for better response to the pandemic for these groups.", "keywords": [ "2019-nCoV", "Address", "Affect", "Age", "Area", "CLIA certified", "COVID-19 detection", "COVID-19 pandemic", "COVID-19 patient", "COVID-19 severity", "COVID-19 testing", "COVID-19 vaccine", "Centers for Disease Control and Prevention (U.S.)", "Centers of Research Excellence", "Communities", "Country", "Dangerousness", "Data", "Data Analyses", "Databases", "Disease Outbreaks", "Early identification", "Ethnic Origin", "Evolution", "Frequencies", "Genbank", "Genetic", "Genetic Recombination", "Genetic Structures", "Genome", "Genomics", "Goals", "Grant", "Guidelines", "Health", "Healthcare", "Hospitals", "Human", "Knowledge", "Molecular", "Molecular Evolution", "Monitor", "Monoclonal Antibody Therapy", "Montana", "Patients", "Pattern", "Pediatric Hospitals", "Pharmacogenetics", "Phase", "Population", "Public Health", "Research", "Reservations", "Resistance", "Resources", "Route", "Rural", "Rural Community", "SARS-CoV-2 B.1.1.7", "SARS-CoV-2 B.1.351", "SARS-CoV-2 genome", "SARS-CoV-2 transmission", "SARS-CoV-2 variant", "Salish and Kootenai Tribes", "Sampling", "Scientist", "Services", "Site", "Structure", "Testing", "Time", "Treatment Efficacy", "United States", "Universities", "Variant", "Viral", "Virulence", "Virus", "adaptive immunity", "genome analysis", "genome sequencing", "host-microbe interactions", "insight", "interest", "metropolitan", "neutralizing monoclonal antibodies", "novel", "novel vaccines", "pandemic disease", "research clinical testing", "response", "sex", "trend", "tribal Nation", "tribal community", "tribal health", "underserved community", "vaccine efficacy", "variants of concern", "viral transmission", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "10499", "attributes": { "award_id": "3R01MH127961-01A1S1", "title": "Utilizing All of Us data to examine the impact of COVID-19 on mental health among people living with HIV", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 24064, "first_name": "Lori", "last_name": "Scott-Sheldon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-08-16", "end_date": "2023-11-30", "award_amount": 107340, "principal_investigator": { "id": 4919, "first_name": "Xiaoming", "last_name": "Li", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "In response to the NOSI (NOT-PM-22-002), we propose to expand the resilience conceptual framework in our parent grant (1R01MH127961-01A1, 12/2021-11/2026) to a different context (COVID-19) and a new population (people living with HIV [PLWH] in the United States). Further, we propose to explore if a resilience approach can be used to mitigate the negative impacts of COVID-19 on the mental health among PLWH. We will leverage multiple datasets from the All of Us program, including electronic health records (EHR), a series of COVID-19 Participant Experience (COPE) surveys, and other self-reported survey data. Integrating these data from about 12 thousand PLWH who participated in COPE, we will: 1) examine the trends and patterns of mental health outcomes (i.e., psychiatric disorder diagnoses via ICD-10 and mental health assessments via survey) among PLWH before and after the COVID-19 outbreak; and 2) identify protective factors at multiple socioecological levels including the individual level (e.g., resilience), interpersonal level (e.g., social support), and health institutional level (e.g., health service accessibility) that may mitigate the negative impacts of the COVID-19 pandemic on mental health outcomes among PLWH, especially the subgroups with socially disadvantaged status (low income and low education) and stigmatized identities (racial/ethnic minorities, sexual and gender minorities). Based on rich data from a large cohort of PLWH, the findings will advance our understanding of their mental health needs during the pandemic and mental health disparities of PLWH in the US and inform tailored health interventions to improve mental health outcomes among PLWH, especially those from disadvantaged subgroups. Our study goal is aligned with the Office of AIDS Research's and National Institute of Mental Health's research priorities in terms of social sciences studies and health disparities reduction. The proposed study will leverage existing NIH investment, capitalize on a rapid understanding of mental health needs among PLWH, stimulate additional collaborations with the All of Us program, and promote the translation of All of Us data to public health implications. The experience and preliminary data obtained from this supplement will position us for further efforts in utilizing All of Us data to improve mental and other health outcomes of PLWH in the US.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Address", "Affect", "Age-Years", "Aging", "All of Us Research Program", "Anxiety", "Anxiety Disorders", "COVID-19", "COVID-19 impact", "COVID-19 outbreak", "COVID-19 pandemic", "COVID-19 pandemic effects", "COVID-19 vaccination", "Caring", "Chronic Disease", "Code", "Collaborations", "Complement", "Complex", "Data", "Data Analyses", "Data Science", "Diabetes Mellitus", "Diagnosis", "Disadvantaged", "Education", "Electronic Health Record", "Ethnic Origin", "Financial Hardship", "Fostering", "Fright", "Gender Identity", "Goals", "HIV", "Health", "Health Promotion", "Health Services Accessibility", "High Prevalence", "Hypertension", "Immune system", "Impairment", "Income", "Individual", "International Statistical Classification of Diseases and Related Health Problems Tenth Revision (ICD-10)", "Intervention", "Investments", "Knowledge", "Loneliness", "Low income", "Lung diseases", "Measures", "Mental Health", "Mental disorders", "Mental health promotion", "Mood Disorders", "National Institute of Mental Health", "Outcome", "Participant", "Patient Self-Report", "Pattern", "Personal Satisfaction", "Personality Disorders", "Persons", "Population", "Positioning Attribute", "Prevention", "Psyche structure", "Public Health", "Race", "Reduce health disparities", "Research", "Research Priority", "Risk Factors", "SARS-CoV-2 infection", "Sample Size", "Schizophrenia", "Series", "Services", "Sexual and Gender Minorities", "Social Identification", "Social Sciences", "Social support", "Stigmatization", "Stress", "Subgroup", "Substance Use Disorder", "Surveys", "Symptoms", "Testing", "Translations", "United States", "United States National Institutes of Health", "Vulnerable Populations", "base", "cloud based", "cohort", "comorbidity", "design", "disparity reduction", "effective intervention", "ethnic minority", "experience", "health assessment", "health disparity", "high risk", "improved", "large scale data", "multiple datasets", "negative affect", "pandemic disease", "parent grant", "parent project", "programs", "protective factors", "psychologic", "psychosocial wellbeing", "public health emergency", "racial and ethnic", "recruit", "resilience", "response", "sexual identity", "social disadvantage", "social stigma", "socioeconomic disadvantage", "stress related disorder", "theories", "trend" ], "approved": true } }, { "type": "Grant", "id": "10395", "attributes": { "award_id": "1R01MH130460-01", "title": "A Deployment Focused Pragmatic Trial of Optimal Stepped Care Intervention Targeting PTSD and Comorbidity for Acutely Hospitalized Injury Survivors Treated in US Trauma Care Systems", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 23282, "first_name": "Michael", "last_name": "Freed", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-01", "end_date": "2027-06-30", "award_amount": 790177, "principal_investigator": { "id": 26376, "first_name": "EILEEN M", "last_name": "BULGER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26377, "first_name": "DOUGLAS F", "last_name": "ZATZICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 159, "ror": "https://ror.org/00cvxb145", "name": "University of Washington", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Life-threatening traumatic exposures requiring presentation to acute care medical settings are endemic in the US in the era of the COVID-19 pandemic, firearm proliferation, and extreme weather events, and constitute both a substantial source of individual suffering and a significant public health burden. Each year in the US, over 30 million individuals present to acute care medical settings after injury, and approximately 2.5 million individuals are so severely injured that they require inpatient hospital admissions. The overarching goal of the Trauma Survivors Outcomes and Support (TSOS) R01 investigation is to advance the sustainable delivery of high quality trauma center mental health screening, intervention and referral procedures for diverse injury survivors. Over the past two decades, the TSOS study team that includes research scientists, trauma surgical policymakers, patients, and frontline clinicians has established a track record of using evidence derived from NIH pragmatic trials to directly target American College of Surgeons Committee on Trauma (College) regulatory policy. The TSOS R01 investigation will refine and test optimal stepped care intervention strategies for diverse injury survivors presenting to acute care medical settings with PTSD and associated comorbidity. This single trauma center site pragmatic trial investigation will individually randomize 424 patients (212 intervention and 212 control) to a brief stepped care intervention versus College required screening and referral control conditions. The stepped care intervention consists of proactive care management, as well as medications and psychotherapy elements targeting PTSD and comorbidity. Blinded follow-up interviews at 3-, 6-, and 12-months post-injury will assess the symptoms of PTSD and related comorbidity for all patients. The emergency department health information exchange will be used to capture population-level automated emergency department/inpatient utilization data for the intent-to-treat sample. The R01 aims to test the primary hypotheses that intervention patients will demonstrate significant reductions in PTSD symptoms and emergency department/inpatient utilization when compared to control patients. The investigation will also explore mediators and moderators of intervention treatment effects that directly address actionable national trauma center quality improvements. A mixed method Rapid Assessment Procedure-Informed Clinical Ethnography implementation process assessment will facilitate the integration of study results into national College policy requirements, guidelines, and verification criteria. A national trauma center survey will elucidate the progression of PTSD and comorbidity screening, intervention and referral for all US level I and II trauma centers. An end-of-study College policy summit will harness pragmatic trial data to inform the capacity for US trauma centers to implement high quality acute care medical mental health services for diverse patient populations.", "keywords": [ "Accident and Emergency department", "Acute", "Address", "Alcohol abuse", "Alcohol consumption", "American College of Surgeons", "Blinded", "COVID-19 pandemic", "Caring", "Clinical", "Data", "Development", "Disease", "Drug usage", "Elements", "Ethnography", "Event", "Feeling suicidal", "Firearms", "Goals", "Guidelines", "Health", "Health Services Research", "Hospitalization", "Individual", "Injury", "Inpatients", "Intervention", "Interview", "Investigation", "Latinx", "Life", "Mediator of activation protein", "Medical", "Mental Depression", "Mental Health Services", "National Institute of Mental Health", "Operative Surgical Procedures", "Outcome", "Patients", "Pharmaceutical Preparations", "Policies", "Population", "Post-Traumatic Stress Disorders", "Procedures", "Process", "Process Assessment", "Protocols documentation", "Psychotherapy", "Public Health", "Quality of Care", "Randomized", "Research", "Sampling", "Science", "Scientist", "Series", "Site", "Site Visit", "Source", "Surveys", "Survivors", "Symptoms", "Testing", "Trauma", "Traumatic injury", "United States National Institutes of Health", "acute care", "alcohol intervention", "alcohol screening", "care systems", "collaboratory", "college", "comorbidity", "extreme weather", "follow-up", "health care delivery", "health service use", "high risk", "implementation process", "injured", "mental health center", "patient population", "patient screening", "post-traumatic symptoms", "pragmatic trial", "psychologic", "rapid technique", "reduce symptoms", "screening", "severe injury", "symposium", "systems research", "trauma care", "trauma centers", "trauma exposure", "treatment effect" ], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1424, "count": 14236 } } }